Abstract
Previous studies identified partial inhibitors and allosteric modulators of 5-hydroxytryptamine ([5-amino-3-(3,4-dichlorophenyl)-1,2-dihydropyrido[3,4-b]pyrazin-7-yl]carbamic acid ethyl ester [SoRI-6238], 4-(2-[bis(4-fluorophenyl)methoxy]ethyl)-1-(2-trifluoromethyl-benzyl)-piperidine [TB-1-099]) and dopamine transporters N-(diphenylmethyl)-2-phenyl-4-quinazolinamine, [SoRI-9804]). We report here the identification of three novel allosteric modulators of the dopamine transporter [N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine [SoRI-20040], N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine [SoRI-20041], and [4-amino-6-[(diphenylmethyl)amino]-5-nitro-2-pyridinyl]carbamic acid ethyl ester [SoRI-2827]]. Membranes were prepared from human embryonic kidney cells expressing the cloned human dopamine transporter (hDAT). [125I]3β-(4′-Iodophenyl)tropan-2β-carboxylic acid methyl ester ([125I]RTI-55) binding and other assays followed published procedures. SoRI-20040, SoRI-20041, and SoRI-2827 partially inhibited [125I]RTI-55 binding, with EC50 values ranging from ∼1.4 to 3 μM and Emax values decreasing as the [125I]RTI-55 concentrations increased. All three compounds decreased the [125I]RTI-55 Bmax value and increased the apparent Kd value in a manner well described by a sigmoid dose-response curve. In dissociation rate experiments, SoRI-20040 (10 μM) and SoRI-20041 (10 μM), but not SoRI-2827 (10 μM), slowed the dissociation of [125I]RTI-55 from hDAT by ∼30%. Using rat brain synaptosomes, all three agents partially inhibited [3H]dopamine uptake, with EC50 values ranging from 1.8 to 3.1 μM and decreased the Vmax value in a dose-dependent manner. SoRI-9804 and SoRI-20040 partially inhibited amphetamine-induced dopamine transporter-mediated release of [3H]1-methyl-4-phenylpyridinium ion from rat caudate synaptosomes in a dose-dependent manner. Viewed collectively, we report several compounds that allosterically modulate hDAT binding and function, and we identify novel partial inhibitors of amphetamine-induced dopamine release.
Footnotes
-
This work was supported by the Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services.
-
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
doi:10.1124/jpet.108.139675.
-
ABBREVIATIONS: DAT, dopamine transporter; NET, norepinephrine transporter; SERT, serotonin transporter; BAT, biogenic amine transporter; HEK, human embryonic kidney; SoRI-9804, N-(diphenylmethyl)-2-phenyl-4-quinazolinamine; SoRI-6238, [5-amino-3-(3,4-dichlorophenyl)-1,2-dihydropyrido[3,4-b]pyrazin-7-yl]carbamic acid ethyl ester; TB-1-099, 4-(2-[bis(4-fluorophenyl)methoxy]ethyl)-1-(2-trifluoromethyl-benzyl)-piperidine; RTI-55, 3β-(4′-iodophenyl)tropan-2β-carboxylic acid methyl ester; DA, dopamine; SoRI-20040, N-(2,2-diphenylethyl)-2-phenyl-4-quinazolinamine; SoRI-20041, N-(3,3-diphenylpropyl)-2-phenyl-4-quinazolinamine; SoRI-2827, [4-amino-6-[(diphenylmethyl)amino]-5-nitro-2-pyridinyl]carbamic acid ethyl ester; hDAT, cloned human dopamine transporter; MPP+, 1-methyl-4-phenylpyridinium ion; GBR12909, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine; BB, binding buffer.
- Received April 2, 2008.
- Accepted April 24, 2008.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|